Core Insights - Becton, Dickinson and Company (BDX) has initiated the XTRACT Registry to evaluate the Rotarex Catheter System for treating peripheral artery disease (PAD) lesions, marking a significant step for the company in enhancing its Peripheral Intervention (PI) business unit [1][3][10] Company Developments - The XTRACT Registry aims to enroll up to 600 patients across the U.S., with follow-up evaluations at 30 days, six months, and 12 months to assess the safety and effectiveness of the Rotarex Catheter System in real-world settings [3] - The Rotarex Catheter System is designed for dual functionality, serving as both an atherectomy and thrombectomy device, which is expected to improve treatment outcomes for PAD lesions [2][10] - BD's management anticipates that the first patient enrollment will generate robust real-world evidence to support the effectiveness of the Rotarex Catheter System, ultimately enhancing patient outcomes and advancing PAD care [7][10] Market Context - PAD currently affects over 21 million Americans and more than 200 million people globally, with untreated cases leading to serious cardiovascular complications and lower limb amputations [6] - The global PAD market is projected to grow from $7.3 billion in 2024 to $11.3 billion by 2033, at a compound annual growth rate (CAGR) of 5.2%, driven by rising disease prevalence and technological advancements [8] Financial Performance - BD has a market capitalization of $53.47 billion and an earnings yield of 7.9%, which is higher than the industry average of 6.6% [5] - In the last reported quarter, BD achieved an earnings surprise of 7.6%, indicating strong performance in its PI business unit, particularly in Peripheral Vascular Disease [5][11] Stock Performance - Following the announcement of the XTRACT Registry, BD's shares declined by nearly 3.8%, despite the potential long-term benefits of the new initiative for top-line growth [4] - Over the past year, BD's stock has decreased by 21.8%, contrasting with a 1.4% rise in the industry and a 13.9% gain in the S&P 500 [12]

Core Insights - BD has enrolled the first patient in the XTRACT™ Registry, a study aimed at evaluating the real-world performance of the Rotarex™ Catheter System for treating peripheral artery disease (PAD) [1][2][4] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [6] - The company employs over 70,000 individuals and operates in nearly every country, addressing significant global health challenges [6] XTRACT™ Registry Details - The XTRACT™ Registry is a prospective, multi-center, single-arm study designed to collect data on the Rotarex™ Catheter System's effectiveness in treating PAD [1][2] - The registry aims to enroll up to 600 patients across 100 clinical sites in the U.S., with follow-up evaluations at 30 days, six months, and 12 months post-procedure [3][4] Rotarex™ Catheter System Features - The Rotarex™ Catheter System utilizes three mechanisms of action to effectively remove plaque and thrombus, functioning as both an atherectomy and thrombectomy device [4] - The device is designed to enhance patient outcomes by modifying and detaching mixed morphology lesions while actively aspirating material away [4] Market Context - PAD affects over 21 million Americans and more than 200 million people globally, with untreated cases leading to serious cardiovascular complications [5]